STAAR Surgical’s New Interim Duo Buy RSUs in Bold Move Amid Leadership Shake‑Up
STAAR Surgical insiders buy 20,787 RSUs amid leadership shake‑up—signals confidence and potential upside for shareholders.
3 minutes to read
STAAR Surgical Co
STAAR Surgical’s Director Holds Steady While Institutional Investor Ramps Up: A Sign of Confidence Amid Market Decline?
STAAR Surgical insider stability signals potential upside: director Le Buhn keeps shares, Broadwood adds millions, while a high‑margin implant pipeline could spark a rebound amid a declining stock and negative P/E.
3 minutes to read
STAAR Surgical Insider Buying Surge: CEO Wei Exercises 21k RSUs Amid Broadwood’s 27k Share Accumulation, Hinting at Confidence Amid Volatility
Insider buying at STAAR Surgical signals confidence amid volatility—Jiang Wei and Broadwood Partners stake big shares, hinting at a rebound in visual‑implant sales.
3 minutes to read
Broadwood Partners Ramps Up STAAR Surgical Stake, Betting on a Visual‑Implant Bounce‑Back
Broadwood Partners keeps buying STAAR Surgical shares, boosting its stake to 1.4% while market price hovers near $22—what does this mean for investors?
3 minutes to read
Broadwood’s Surge: Institutional Buying Signals Confidence in STAAR Surgical Post‑Alcon Collapse
Broadwood Partners’ new stake in STAAR Surgical signals a potential undervaluation, as the firm backs the company’s return to core ophthalmic devices after a failed Alcon merger.
3 minutes to read